keyword
MENU ▼
Read by QxMD icon Read
search

Intrahepatic cholangiocarcinoma

keyword
https://www.readbyqxmd.com/read/28211504/novel-preoperative-nomogram-for-prediction-of-futile-resection-in-patients-undergoing-exploration-for-potentially-resectable-intrahepatic-cholangiocarcinoma
#1
Kwangwoo Nam, Dae Wook Hwang, Ju Hyun Shim, Tae Jun Song, Sang Soo Lee, Dong-Wan Seo, Sung Koo Lee, Myung-Hwan Kim, Ki-Hun Kim, Shin Hwang, Kwang-Min Park, Young-Joo Lee, Minkyu Han, Do Hyun Park
Surgical resection is the treatment of choice for intrahepatic cholangiocarcinoma (IHCC). However, discrepancies between preoperative workup and intraoperative findings can occur, resulting in unexpected and unfavorable surgical outcomes. The aim of this study was to develop a feasible preoperative nomogram to predict futile resection of IHCC. A total of 718 patients who underwent curative-intent surgery for IHCC between January 2005 and December 2014 were included. The patients were divided into a training cohort (2005-2010, n = 377) and validation cohort (2011-2014, n = 341)...
February 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28206944/improved-postoperative-survival-for-intraductal-growth-subtype-of-intrahepatic-cholangiocarcinoma
#2
Laura L Dover, Rojymon Jacob, Thomas N Wang, Joseph H Richardson, David T Redden, Peng Li, Derek A DuBay
Intrahepatic cholangiocarcinoma (ICC) is classified according to the following subtypes: massforming (MF), periductal infiltrating (PI), and intraductal growth (IG). The aim of this study is to measure the association between ICC subtypes and patient survival after surgical resection. Data were abstracted on all patients treated with definitive resections of ICC at a single institution between 2000 and 2011 with at least three years follow-up. Survival estimates were quantified using Kaplan-Meier curves and compared using the log-rank test...
November 1, 2016: American Surgeon
https://www.readbyqxmd.com/read/28205002/prognostic-impacts-of-postoperative-complications-in-patients-with-intrahepatic-cholangiocarcinoma-after-curative-operations
#3
Tatsunori Miyata, Yo-Ichi Yamashita, Takanobu Yamao, Naoki Umezaki, Masayo Tsukamoto, Yuki Kitano, Kensuke Yamamura, Kota Arima, Takayoshi Kaida, Shigeki Nakagawa, Katsunori Imai, Daisuke Hashimoto, Akira Chikamoto, Takatoshi Ishiko, Hideo Baba
BACKGROUND: The postoperative complication is one of an indicator of poor prognosis in patients with several gastroenterological cancers after curative operations. We, herein, examined prognostic impacts of postoperative complications in patients with intrahepatic cholangiocarcinoma after curative operations. METHODS: We retrospectively analyzed 60 patients with intrahepatic cholangiocarcinoma who underwent primary curative operations from June 2002 to February 2016...
February 15, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28194813/microrna-191-acts-as-a-tumor-promoter-by-modulating-the-tet1-p53-pathway-in-intrahepatic-cholangiocarcinoma
#4
Hao Li, Zun-Qiang Zhou, Zhang-Ru Yang, Da-Nian Tong, Jiao Guan, Bao-Jie Shi, Jia Nie, Xian-Ting Ding, Bin Li, Guang-Wen Zhou, Zheng-Yun Zhang
: Current treatment of intrahepatic cholangiocarcinoma (ICC) remains ineffective because knowledge of ICC carcinogenesis is unclear. Increasing evidence suggests that microRNAs (miRNAs), including miRNA-191, play an important role in tumorigenesis, but expression and biological functions of miRNA-191 in ICC remain to be established. This study aimed to investigate the functions and underlying mechanisms of miRNA-191 in ICC. ICC miRNA profiles were generated in 5 pairs of ICC and matched to normal bile duct tissues by next-generation sequencing technology; ICC miRNA profiles were verified in 18 pairs of ICC tissues and normal bile duct tissues by quantitative reverse transcription PCR (qRT-PCR)...
February 14, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28194791/comparative-performances-of-the-7th-and-the-8th-editions-of-the-american-joint-committee-on-cancer-staging-systems-for-intrahepatic-cholangiocarcinoma
#5
Gaya Spolverato, Fabio Bagante, Matthew Weiss, Sorin Alexandrescu, Hugo P Marques, Luca Aldrighetti, Shishir K Maithel, Carlo Pulitano, Todd W Bauer, Feng Shen, George A Poultsides, Oliver Soubrane, Guillaume Martel, Bas Groot Koerkamp, Alfredo Guglielmi, Endo Itaru, Timothy M Pawlik
BACKGROUND: We sought to evaluate and validate the 8th edition of the AJCC classification using a multi-institutional cohort of patients with intrahepatic cholangiocarcinoma (ICC). METHODS: Patients undergoing curative-intent hepatic resection for ICC between 1990 and 2015 at 14 major hepatobiliary centers were included and were staged according to 7th and 8th editions AJCC criteria. RESULTS: A total of 1154 patients underwent liver resection for ICC...
February 14, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28192597/a-phase-2-and-biomarker-study-of-cabozantinib-in-patients-with-advanced-cholangiocarcinoma
#6
Lipika Goyal, Hui Zheng, Matthew B Yurgelun, Thomas A Abrams, Jill N Allen, James M Cleary, Michelle Knowles, Eileen Regan, Amanda Reardon, Anna Khachatryan, Rakesh K Jain, Valentina Nardi, Darrell R Borger, Dan G Duda, Andrew X Zhu
BACKGROUND: Advanced cholangiocarcinoma carries a poor prognosis, and no standard treatment exists beyond first-line gemcitabine/platinum-based chemotherapy. A single-arm, phase 2 and biomarker study of cabozantinib, a multikinase inhibitor with potent activity against vascular endothelial growth factor receptor 2 (VEGFR2) and MET, was performed for patients with advanced refractory cholangiocarcinoma. METHODS: Previously treated patients with unresectable or metastatic cholangiocarcinoma received cabozantinib (60 mg orally and daily on a continuous schedule)...
February 13, 2017: Cancer
https://www.readbyqxmd.com/read/28179982/spontaneous-biloma-due-to-an-intrahepatic-cholangiocarcinoma-an-extremely-rare-case-report-with-long-term-survival-and-literature-review
#7
Georgios K Georgiou, Athina Tsili, Anna Batistatou, Alexandra Papoudou-Bai, Georgios Papadopoulos, Michalis Fatouros, Georgios K Glantzounis
Cholangiocarcinomas are tumors that arise from the ductal epithelium of the intrahepatic or extra-hepatic bile ducts. Patients are usually asymptomatic or may present with weight loss, fatigue, loss of appetite and abdominal pain (intrahepatic cholangiocarcinomas) or jaundice (extra-hepatic cholangiocarcinomas). Subcapsular bile vessel rupture, due to intrahepatic cholangiocarcinoma, is an extremely rare clinical presentation, which is an emergent and potentially life-threatening complication. We report the case of a 79-year-old female patient suffering from an intrahepatic cholangiocarcinoma that completely obliterated the left main hepatic duct...
February 2017: Annals of Medicine and Surgery
https://www.readbyqxmd.com/read/28169208/evaluation-of-prognostic-factors-and-implication-of-lymph-node-dissection-in-intrahepatic-cholangiocarcinoma-10-year-experience-at-a-tertiary-referral-center
#8
Miao-Erh Chang, Hao-Jan Lei, Ming-Huang Chen, Yi-Chen Yeh, Chung-Pin Li, Yi-Ping Hung, Cheng-Yuan Hsia, Chieu-An Liu, Gar-Yang Chau, Yee Chao
BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver malignancy, and surgical resection remains the only potentially curative treatment. However, the existing literature indicates that those prognostic factors associated with outcome after surgery remain poorly defined. METHODS: Data were retrospectively collected from 103 patients with ICC who underwent surgical resection between 2005 and 2014. The patients were divided into two groups: one with (D1) and one without (D0) lymph node dissection of hepatic hilum according to the surgery performed...
February 3, 2017: Journal of the Chinese Medical Association: JCMA
https://www.readbyqxmd.com/read/28166242/combination-of-anti-l1-cell-adhesion-molecule-antibody-and-gemcitabine-or-cisplatin-improves-the-therapeutic-response-of-intrahepatic-cholangiocarcinoma
#9
Seulki Cho, Tae Sup Lee, In Ho Song, A-Ram Kim, Yoon-Jin Lee, Haejung Kim, Haein Hwang, Mun Sik Jeong, Seung Goo Kang, Hyo Jeong Hong
Cholangiocarcinoma has a poor prognosis and is refractory to conventional chemotherapy and radiation therapy. Improving survival of patients with advanced cholangiocarcinoma urgently requires the development of new effective targeted therapies in combination with chemotherapy. We previously developed a human monoclonal antibody (mAb) Ab417 that binds to both the human and mouse L1 cell adhesion molecule (L1CAM) with high affinities. In the present study, we observed that Ab417 exhibited tumor targeting ability in biodistribution studies and dose-dependent tumor growth inhibition in an intrahepatic cholangiocarcinoma (Choi-CK) xenograft mouse model...
2017: PloS One
https://www.readbyqxmd.com/read/28162004/molecular-profiling-of-intrahepatic-cholangiocarcinoma-the-search-for-new-therapeutic-targets
#10
Douglas V N P Oliveira, Shanshan Zhang, Xin Chen, Diego F Calvisi, Jesper B Andersen
Intrahepatic cholangiocarcinoma (iCCA) is the second most frequent primary tumor of the liver and a highly lethal disease. Therapeutic options for advanced iCCA are limited and ineffective due to the largely incomplete understanding of the molecular pathogenesis of this deadly tumor. Areas covered: The present review article outlines the main studies and resulting discoveries on the molecular profiling of iCCA, with a special emphasis on the different techniques used for this purpose, the diagnostic and prognostic markers identified, as well as the genes and pathways that could be potentially targeted with innovative therapies...
February 4, 2017: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28155327/intrahepatic-clear-cell-cholangiocarcinoma-an-uncommon-histologic-subtype-case-report-and-literature-review
#11
Samuel Raimundo Fernandes, Cilénia Baldaia, Hugo Pinto Marques, Francisco Tortosa, Fernando Ramalho
Clear-cell cholangiocarcinoma is a very uncommon variant of cholangiocarcinoma with a largely unknown natural history and prognosis. We report a case of a 51-year-old previously healthy woman presenting with a large liver nodule found on routine imaging. Needle biopsy of the lesion suggested a non-hepatocellular carcinoma. After extensive workup for other primary neoplasms, the patient underwent a partial hepatectomy. Histopathology was compatible with a moderately differentiated clear-cell cholangiocarcinoma...
February 3, 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28154778/surgical-treatment-of-intrahepatic-cholangiocarcinoma-a-retrospective-study-of-104-cases
#12
Xiao-Dong Xun, Qiang Li
OBJECTIVE: To explore the clinicopathological features, surgical treatment techniques, and prognostic risk factors of intrahepatic cholangiocarcinoma (ICC). METHODS: A total of 104 ICC cases were collected from January 2008 to December 2013 at Tianjin Medical University Cancer Institute and Hospital and divided into the hepatic hilum lymphadenectomy (HLL, 21 cases), extended hepatic hilum lymphadenectomy (EHLL, 12 cases), and non-lymphadenectomy (NL, 71 cases) groups...
December 2016: Cancer Biology & Medicine
https://www.readbyqxmd.com/read/28146430/intratumoral-heterogeneity-of-intrahepatic-cholangiocarcinoma
#13
Dirk Walter, Claudia Döring, Magdalena Feldhahn, Florian Battke, Sylvia Hartmann, Ria Winkelmann, Markus Schneider, Katrin Bankov, Andreas Schnitzbauer, Stefan Zeuzem, Martin Leo Hansmann, Jan Peveling-Oberhag
No personalized therapy regimens could demonstrate a benefit in survival of intrahepatic cholangiocarcinoma (iCCA). Since genetic heterogeneity might influence single biopsy based targeted therapy or the outcome of clinical trials, aim of the present study was to investigate intratumoral heterogeneity of iCCA by whole exome sequencing. Therefore, samples from tumor center and tumor periphery of large iCCA lesions as well as a control from healthy liver tissue were obtained from four patients and whole exome sequencing was performed...
January 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28143798/diagnostic-histopathology-of-hepatocellular-carcinoma-a-case-based-review
#14
Rashmi M Agni
Hepatocellular carcinoma (HCC) is the most common primary hepatic malignant neoplasm in adults. Clinically, it tends to present late, and its prognosis historically has been poor, due to limited treatment options at the more advanced stage. A multidisciplinary approach for surveillance and early diagnosis of hepatocellular carcinoma in high-risk populations, combined with advances in surgical and other forms of ablative or chemotherapy, has greatly improved outcomes for patients with this tumor. Liver biopsies for HCC are becoming rare, being performed only for lesions that are atypical on imaging, to avoid the risk of bleeding or of inadvertently seeding the needle tract with HCC...
December 21, 2016: Seminars in Diagnostic Pathology
https://www.readbyqxmd.com/read/28139862/the-pd-1-pd-l1-axis-may-be-aberrantly-activated-in-occupational-cholangiocarcinoma
#15
Yasunori Sato, Masahiko Kinoshita, Shigekazu Takemura, Shogo Tanaka, Genya Hamano, Shoji Nakamori, Masahiro Fujikawa, Yasuhiko Sugawara, Takatsugu Yamamoto, Akira Arimoto, Minako Yamamura, Motoko Sasaki, Kenichi Harada, Yasuni Nakanuma, Shoji Kubo
An outbreak of cholangiocarcinoma in a printing company was reported in Japan, and these cases were regarded as an occupational disease (occupational cholangiocarcinoma). This study examined the expression status of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) in occupational cholangiocarcinoma. Immunostaining of PD-1, PD-L1, CD3, CD8, and CD163 was performed using tissue sections of occupational cholangiocarcinoma (n = 10), and the results were compared with those of control cases consisting of intrahepatic (n = 23) and extrahepatic (n = 45) cholangiocarcinoma...
January 31, 2017: Pathology International
https://www.readbyqxmd.com/read/28138905/a-case-of-concomitant-colitic-cancer-and-intrahepatic-cholangiocarcinoma-during-follow-up-for-ulcerative-colitis
#16
Kazuyo Tsuchiya, Atsushi Nanashima, Takuto Ikeda, Shiro Minami, Motoaki Nagano, Takeomi Hamada, Koichi Yano, Yoshiro Fujii
Colitis-associated colorectal cancer (CAC) is known to occur in long-standing and extensive ulcerative colitis (UC). Furthermore, UC is known to complicate primary sclerosing cholangitis (PSC), which subsequently results in an increased risk of developing cholangiocarcinoma. We report a case of colitis-associated rectal cancer (CARC) accompanied by intrahepatic cholangiocarcinoma (ICC) based on UC and PSC. A 73-year-old man had suffered from UC for 19 years. During surveillance colonoscopy, a tumor was found in the rectum that was pathologically diagnosed as CARC from the resected specimen...
January 30, 2017: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/28133124/-surgical-resection-after-gemcitabine-plus-cisplatin-chemotherapy-for-intrahepatic-cholangiocarcinoma-with-multiple-lymph-node-metastases-report-of-a-case
#17
Takahiro Otani, Jun Sakata, Hitoshi Kameyama, Ayaka Otani, Yuki Hirose, Hiroshi Tamura, Yuta Morimoto, Kohei Miura, Kei Yoshino, Tomoki Kido, Takashi Kobayashi, Kazuhiko Endo, Toshifumi Wakai
An 82-year-old man with upper abdominal pain was referred to our hospital because of an elevated serum CEA level and dilatation of the intrahepatic bile ducts on ultrasonography.Computed tomography revealed a hypovascular mass measuring 5.0 cm in size in the lateral section, dilatation of the peripheral intrahepatic bile ducts, and swollen lymph nodes around the lesser curvature of the stomach, the common hepatic artery, and the paraaorta.He was diagnosed with unresectable intrahepatic cholangiocarcinoma, and he received chemotherapy with biweekly gemcitabine plus cisplatin...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28130841/dmbt1-expression-in-biliary-carcinogenesis-with-correlation-of-clinicopathological-data
#18
Benjamin Goeppert, Stephanie Roessler, Natalia Becker, Manuela Zucknick, Monika Nadja Vogel, Arne Warth, Anita Pathil-Warth, Arianeb Mehrabi, Peter Schirmacher, Jan Mollenhauer, Marcus Renner
AIMS: Deleted in Malignant Brain Tumors 1 (DMBT1) exerts functions in the regulation of epithelial differentiation and inflammation and has been proposed as tumor suppressor. Since chronic inflammation is a hallmark of cholangiocarcinogenesis, the aim of the study was to investigate the expression of DMBT1 in biliary tract cancer (BTC) and to correlate the expression with clinicopathological data. METHODS AND RESULTS: The expression of DMBT1 protein was examined immunohistochemically in 157 BTC patients (41 intrahepatic (ICC), 60 extrahepatic cholangiocarcinomas (ECC), and 56 adenocarcinomas of the gallbladder (GBAC))...
January 28, 2017: Histopathology
https://www.readbyqxmd.com/read/28124125/impact-of-incidental-misdiagnosed-intrahepatic-cholangiocarcinoma-and-combined-hepatocellular-cholangiocarcinoma-on-the-outcomes-of-liver-transplantation-an-institutional-case-series-and-literature-review
#19
REVIEW
Rahul Gupta, Junichi Togashi, Nobuhisa Akamatsu, Yoshihiro Sakamoto, Norihiro Kokudo
Intrahepatic cholangiocarcinoma (ICC) or combined hepatocellular cholangiocarcinoma (cHCC-CC) is considered to be contraindications for liver transplantation (LT); however, recent studies have shown that the outcomes of LT in small incidental ICC/cHCC-CC tumors are comparable to those in HCC. Studies reporting the survival outcome of patient(s) undergoing LT and found to have incidental or misdiagnosed ICC and/or cHCC-CC in liver explants were reviewed. Our institutional data were also included in the review analysis...
January 25, 2017: Surgery Today
https://www.readbyqxmd.com/read/28124097/pan-mutant-idh1-inhibitor-bay-1436032-for-effective-treatment-of-idh1-mutant-astrocytoma-in-vivo
#20
Stefan Pusch, Sonja Krausert, Viktoria Fischer, Jörg Balss, Martina Ott, Daniel Schrimpf, David Capper, Felix Sahm, Jessica Eisel, Ann-Christin Beck, Manfred Jugold, Viktoria Eichwald, Stefan Kaulfuss, Olaf Panknin, Hartmut Rehwinkel, Katja Zimmermann, Roman C Hillig, Judith Guenther, Luisella Toschi, Roland Neuhaus, Andrea Haegebart, Holger Hess-Stumpp, Markus Bauser, Wolfgang Wick, Andreas Unterberg, Christel Herold-Mende, Michael Platten, Andreas von Deimling
Mutations in codon 132 of isocitrate dehydrogenase (IDH) 1 are frequent in diffuse glioma, acute myeloid leukemia, chondrosarcoma and intrahepatic cholangiocarcinoma. These mutations result in a neomorphic enzyme specificity which leads to a dramatic increase of intracellular D-2-hydroxyglutarate (2-HG) in tumor cells. Therefore, mutant IDH1 protein is a highly attractive target for inhibitory drugs. Here, we describe the development and properties of BAY 1436032, a pan-inhibitor of IDH1 protein with different codon 132 mutations...
January 25, 2017: Acta Neuropathologica
keyword
keyword
77684
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"